Production (Stage)
Xeris Biopharma Holdings, Inc.
XERS
$4.83
-$0.05-1.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 30.01% | 11.92% | -2.13% | 16.62% | 17.20% |
| Total Depreciation and Amortization | -4.84% | -4.07% | -4.87% | -1.02% | 2.93% |
| Total Amortization of Deferred Charges | 47.00% | 36.37% | 27.47% | 24.34% | 18.11% |
| Total Other Non-Cash Items | 155.30% | 79.24% | 184.06% | 1,009.98% | -19.11% |
| Change in Net Operating Assets | -743.60% | -40.13% | 134.18% | 85.79% | 107.79% |
| Cash from Operations | 35.15% | 21.36% | 55.41% | 48.76% | 48.91% |
| Capital Expenditure | 67.25% | 61.64% | 65.53% | 50.43% | -187.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 23.02% | 253.73% | 211.38% | 188.37% | 232.73% |
| Cash from Investing | 33.81% | 181.33% | 183.18% | 173.67% | 212.88% |
| Total Debt Issued | -100.00% | -- | 2.21% | 2.21% | 2.21% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 489.90% | 198.28% | 30.03% | 30.03% | 25.60% |
| Repurchase of Common Stock | -131.79% | -270.07% | -268.71% | -284.85% | -291.26% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -898.40% | -21,593.33% | -441.10% | -3,028.85% |
| Cash from Financing | -106.28% | 2,342.28% | -29.20% | -29.01% | -28.86% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -137.57% | 107.45% | 138.12% | 125.11% | 123.91% |